The American Diabetes Association's 2024 Standards of Care recommend GLP-1 receptor agonists or dual GIP/GLP-1 receptor agonists like tirzepatide as preferred second-line therapy for patients with established atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease, regardless of A1C [4]
FDA-approved brand Wegovy runs $199 intro or $349 ongoing through NovoCare self-pay
Thank you Shipping was so quick and instructions were very clear
Mounjaro use may indirectly cause fatigue through calorie deficits, dehydration from stomach side effects, and low blood sugar, which can leave a person feeling drained
This is standard across all compounded tirzepatide providers
Instead of delaying care due to cost, patients can begin treatment, attend follow-up visits, and remain consistent long enough to see meaningful progress and better health